Venlafaxine and paroxetine in treatment-resistant depression
| العنوان: | Venlafaxine and paroxetine in treatment-resistant depression |
|---|---|
| المؤلفون: | M F Poirier, P Boyer |
| المصدر: | British Journal of Psychiatry. 175:12-16 |
| بيانات النشر: | Royal College of Psychiatrists, 1999. |
| سنة النشر: | 1999 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Venlafaxine Hydrochloride, Drug Resistance, Venlafaxine, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Humans, Psychiatry, Adverse effect, Depression (differential diagnoses), Depressive Disorder, Dose-Response Relationship, Drug, Middle Aged, Cyclohexanols, medicine.disease, Paroxetine, Antidepressive Agents, 030227 psychiatry, Psychiatry and Mental health, Treatment Outcome, Antidepressant, Female, Reuptake inhibitor, Psychology, Treatment-resistant depression, 030217 neurology & neurosurgery, medicine.drug |
| الوصف: | BackgroundAbout one-third of patients fail to respond to initial antidepressant therapy, which suggests a need for more effective drugs.AimsTo compare the efficacy and safety of venlafaxine and paroxetine in 122 patients with non-chronic treatment-resistant depression.MethodIn-patients or out-patients satisfying DSM – III – R criteria for major depression in evolution for less than eight months, having a baseline HAM–D score 18 and a HAM – D Item 3 score < 3 were eligible. Patients were required to have a history of resistance to two previous antidepressant treatments and a CGI improvement score of 3 at the beginning of treatment. Doses were adjusted to 200–300 mg/day for venlafaxine and 30–40 mg/day for paroxetine.ResultsFor the observed-case analysis, the response rate was 51.9% for venlafaxine and 32.7% for paroxetine (P=0.044), and a remission was achieved in 42.3% of venlafaxine-treated and 20.0% of paroxetine-treated patients (P=0.01). The incidence of adverse effects was comparable between treatment groups.ConclusionsVenlafaxine showed some evidence of superiority to paroxetine in this difficult-to-treat patient population. |
| تدمد: | 1472-1465 0007-1250 |
| DOI: | 10.1192/bjp.175.1.12 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ee9a910fe7c8bd37255d5a72554777f https://doi.org/10.1192/bjp.175.1.12 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....6ee9a910fe7c8bd37255d5a72554777f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14721465 00071250 |
|---|---|
| DOI: | 10.1192/bjp.175.1.12 |